Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Nivo + ipi in unresectable stage III/IV melanoma

Michael Postow, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, talks through data from a phase II study (NCT03122522) evaluating the need for more than two doses of nivolumab and ipilimumab combination immunotherapy in patients with unresectable stage III/IV melanoma.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),